Researchers from the HIV Prevention Trials Network (HPTN) presented results from HPTN 091 ("I Am Study") at the HIVR4P 2024 ...
PrEP uptake and adherence were evaluated as the primary study outcome at week 26, with adherence defined as taking four or more pills per week based on tenofovir detection in dried blood spots ...
The highest risk factor of acquiring HIV while taking PrEP is poor adherence. When breakthrough infections have been reported, they have typically occurred when people on PrEP have been exposed to HIV ...
Harmony Garges, M.D, senior vice president, chief medical officer and head of global medical at ViiV Healthcare, highlighted ...
PrEP is used to protect at-risk people such as an HIV-negative individual with an HIV-positive partner and requires high levels of adherence to be effective, which can be tricky to achieve with ...
Four of the six profiled studies of oral TDF-based PrEP showed strong evidence of efficacy for all risk groups. The two trials that did not were hampered by low drug adherence by participants.
Studies from OPERA and Trio cohorts provide further real-world evidence supporting CAB LA for PrEP’s high effectiveness and adherence in preventing HIV acquisition Patient-reported results for CAB LA ...
In this randomized controlled trial, among adolescent girls and young women, it was found that twice-yearly lenacapavir ...
These changes enhance the state’s ability to carry out an execution ... by ensuring we have the infrastructure in place to ...
Objective Physical activity confers physical and psychosocial benefits for cancer patients and decreases morbidity and mortality, but adherence varies. High-intensity interval training (HIIT) is ...
PrEP adherence based on dried blood spot results was confirmed for 50% and 51% of the participants, respectively. Retention was comparably high in both study arms (84% and 87%, respectively).
Four of the six profiled studies of oral TDF-based PrEP showed strong evidence of efficacy for all risk groups. The two trials that did not were hampered by low drug adherence by participants.